Drugs / RO7293583
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04551352 | Oct 2020 → Jul 2022 | cutaneous melanoma, mucosal melanoma, uveal melanoma | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7293583 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04551352 ↗ |
| Known as | RG6232 | “TYRP1-TCB (RO7293583; RG6232) is a T-cell engaging bispecific (TCB) antibody that targets tyrosinase-related protein 1 (TYRP1)” PMID 38577337 ↗ Mar 2024 |
| Known as | TYRP1-TCB | “TYRP1-TCB (RO7293583; RG6232) is a T-cell engaging bispecific (TCB) antibody that targets tyrosinase-related protein 1 (TYRP1)” PMID 38577337 ↗ Mar 2024 |
| Action | Deplete | “thereby directing T cells to kill TYRP1-expressing tumor cells” PMID 38577337 ↗ Mar 2024 |
| Route | Intravenous | “intravenous (IV)” NCT04551352 ↗ |
| Target | TYRP1 | “targets tyrosinase-related protein 1 (TYRP1)” PMID 38577337 ↗ Mar 2024 |